Daiichi Sankyo Company, Limited

Daiichi Pharmaceutical Col, Ltd.

Hirohiko Arisawa

Hiroaki Masunaga

Kanji Higashio

Hiromi Ogawa

Keiji Hayashi

The present invention provides methods of preventing and/or treating multiple organ failure comprising the step of administering a therapeutically effective amount of agent comprising tumor cytotoxic factor-II (TCF-II) or hepatocyte growth factor (HGF). Methods of the present invention will be useful for preventing and/or treating the development of multiple organ failure resulting from burn, disseminated intravascular coagulation (DIC), circulatory failure, hemorrhagic shock, infectious disease, acute pancreatitis, ischemic disorder, hepatorenal syndrome, gastrointestinal hemorrhage, nutritional metabolic failure, terminal cancer, acquired immunodeficiency syndrome (AIDS), deterioration of systemic conditions due to radiation affection, and cachexia.

Agent for preventing and/or treating multiple organ failure

Novel dry skin remedies useful for treatment dry skin, containing as the active ingredient spiro &lsqb;oxathiolane-quinuclidine&rsqb; derivatives represented by general formula (I) or acid addition salts thereof, desirably cis-2-methylspiro &lsqb;1,3-oxathiolane-5,3&prime;-quinuclidine&rsqb; hydrochloride. The remedies promote the secretion of sebaceous and sweat glands through oral or parenteral administration to treat dry skin, thus being useful as drugs.

Growing community of inventors

Minamikawachi-machi, Japan

Hirohiko Arisawa